For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 98,924 | 114,249 | 101,200 | |
| General and administrative | 15,438 | 17,513 | 26,024 | |
| Total operating expenses | 114,362 | 131,762 | 127,224 | |
| Interest income, net | 5,333 | 5,604 | 6,337 | |
| Other (income) expense, net | -54 | 250 | 1,187 | |
| Loss before provision for income taxes | -109,083 | -125,908 | -119,700 | |
| Provision for income taxes | 1,552 | 594 | 913 | |
| Net loss | -110,635 | -126,502 | -120,613 | |
| Basic EPS | -0.61 | -0.73 | -0.71 | |
| Diluted EPS | -0.61 | -0.73 | -0.71 | |
| Basic Average Shares | 181,513,386 | 173,643,829 | 170,872,994 | |
| Diluted Average Shares | 181,513,386 | 173,643,829 | 170,872,994 | |
Immunovant, Inc. (IMVT)
Immunovant, Inc. (IMVT)